Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Modified TPF Followed by CCRT in LASCCHN
NCT05527782Phase 2Active, not recruiting
- Sponsor
- Hospital Universitario Doctor Peset
- Start
- May 2019
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin and fluorouracil in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Hospital Universitario Doctor Peset. Primary endpoint: Objective Response Rate. Started May 2019; status: active, not recruiting.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05527782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05527782.